<DOC>
	<DOCNO>NCT02338167</DOCNO>
	<brief_summary>Among patient breast cancer subgroup patient metastasis consider group patient bad prognosis . Not regard therapy decision also regard quality assure healthcare health economics entity patient remain challenge . Recently , novel advance breast cancer therapy aim target therapy tumor entity identification patient , great therapy benefit least side effect expect . However molecular assessment patient tumor metastatic situation perform routine basis many case tumor characteristic primary tumor consider reliable enough make therapy decision metastatic patient . Although molecular reassessment tumor characteristic tumor material metastasis recommend national guideline , minority patient biopsied , invasiveness procedure , even though biopsy relate complication report rare . With modern analytic method blood base biomaterial seem opportunity correlate blood base tumor assessment actual characteristic tumor . These include expression analysis , tumor mutation analysis , tumor gene copy number abberations others . One main aim PRAEGNANT study therefore establish infrastructure comprehensive analysis tumor metastatic molecular characteristic patient tumor . Furthermore impact health care relate outcomes health economics novel approach integration patient study conduct health care awareness study aim PRAEGNANT study .</brief_summary>
	<brief_title>Praegnant Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Adult woman age â‰¥18 year Patients diagnosis invasive breast cancer ( German : Mammakarzinom , oppose `` noninvasive '' = ductales Carcinoma situ ; irrespective status BC , e.g . TNM , receptor status etc . ) Patients , willing able sign inform consent form Patients metastatic locally advanced , inoperable disease proven clinical measure ( i.e . standard image ) Patients sign inform consent form Patients , eligible observation due nonavailability and/or severe comorbidities evaluate treat physician Patients diagnosis metastatic locally advanced , inoperabe breast cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>